试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-09
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
编号:NCT02245230登记状态:提前终止企业 / 申办者:Vanderbilt University
药物 / 成分:Angiotensin (1-7)、Trimethaphan、Phenylephrine
登记的停止原因(原文):We were not able to enroll adequate number of participants that met the inclusion/exclusion criteria, and we run out of funding.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-09
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
编号:NCT03420521登记状态:提前终止企业 / 申办者:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
药物 / 成分:Nivolumab、Ipilimumab
登记的停止原因(原文):Loss of funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-09
A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
编号:NCT03439514登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:ARRY-371797 (PF-07265803)、Placebo
登记的停止原因(原文):The Sponsor terminated the study due to futility. The decision to stop the study was not based on safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-09
High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer
编号:NCT03870529登记状态:提前终止企业 / 申办者:Wake Forest University Health Sciences
药物 / 成分:Vitamin A Compound、Therapeutic Conventional Surgery
登记的停止原因(原文):Slow accruals
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-08
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma
编号:NCT03502577登记状态:提前终止企业 / 申办者:Fred Hutchinson Cancer Center
药物 / 成分:BCMA-specific CAR-expressing T Lymphocytes、Cyclophosphamide、Fludarabine、Gamma-Secretase Inhibitor LY3039478
登记的停止原因(原文):Closed per SRC Low Accrual Policy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-08
Reparixin in COVID-19 Pneumonia - Efficacy and Safety
编号:NCT04794803登记状态:提前终止企业 / 申办者:Dompé Farmaceutici S.p.A
药物 / 成分:Reparixin、Standard of care
登记的停止原因(原文):The sponsor has decided to start with a separate protocol for phase 3 and therefore this study was terminated with only phase 2.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-08
Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults
编号:NCT05212818登记状态:提前终止企业 / 申办者:Techfields Inc
药物 / 成分:TF0023
登记的停止原因(原文):Low patient accrual.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-05
Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome
编号:NCT00673816登记状态:提前终止企业 / 申办者:National Eye Institute (NEI)
药物 / 成分:Sunitinib Malate
登记的停止原因(原文):Inability to recruit and adequate number of participants
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-05
Probiotic Lactobacillus GG to Eliminate VRE Colonization
编号:NCT00756262登记状态:提前终止企业 / 申办者:Tufts Medical Center
药物 / 成分:Lactobacillus GG or Culturelle
登记的停止原因(原文):Insufficient recruitment, no additional funding available
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-01-05
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
编号:NCT03149549登记状态:提前终止企业 / 申办者:CytomX Therapeutics
药物 / 成分:CX-2009
登记的停止原因(原文):Covid Pandemic; Business Decision to separate Phase 2 to new study
查看官方原始记录 ↗